Manufacturer of Controlled Substances; Notice of Registration; Cambrex Charles City, Inc., 14299-14300 [2014-05495]
Download as PDF
<![CDATA[
14299
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in
support of product development.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Nektar Therapeutics to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. The DEA has investigated
Nektar Therapeutics to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Schedule
Thebaine (9333) ...........................
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Johnson Matthey, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. The DEA has
investigated, Johnson Matthey, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05489 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2014–05500 Filed 3–12–14; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.
DEPARTMENT OF JUSTICE
By Notice dated November 5, 2013,
and published in the Federal Register
on November 18, 2013, 78 FR 69133,
Johnson Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Manufacturer of Controlled
Substances; Notice of Registration;
Pharmacore, Inc.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
VerDate Mar<15>2010
17:33 Mar 12, 2014
Drug Enforcement Administration
I
II
II
II
II
II
II
II
II
II
II
Jkt 232001
By Notice dated September 27, 2013,
and published in the Federal Register
on October 25, 2013, 78 FR 64017,
PharmaCore, Inc., 4180 Mendenhall
Oaks Parkway, High Point, North
Carolina 27265, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance as active
pharmaceutical ingredients (API) for
clinical trials.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
PharmaCore, Inc., to manufacture the
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
listed basic class of controlled substance
is consistent with the public interest at
this time. The DEA has investigated
PharmaCore, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05504 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2013,
and published in the Federal Register
on October 25, 2013, 78 FR 64017,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
E:\FR\FM\13MRN1.SGM
13MRN1
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
14300
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
Drug
Schedule
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers, for dosage form
development, for clinical trials, and for
use in stability qualification studies.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc., to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. The DEA
has investigated Cambrex Charles City,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket Number: OSHA–2014–0004]
Occupational Safety and Health
Administration (OSHA), DOL.
ACTION: Request for nominations to
serve on the Whistleblower Protection
Advisory Committee.
DEPARTMENT OF JUSTICE
The Assistant Secretary of
Labor for Occupational Safety and
Health requests nominations for
membership on the Whistleblower
Protection Advisory Committee
(WPAC).
SUMMARY:
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration; GE
Healthcare
TKELLEY on DSK3SPTVN1PROD with NOTICES
[FR Doc. 2014–05484 Filed 3–12–14; 8:45 am]
AGENCY:
BILLING CODE 4410–09–P
By Notice dated October 16, 2013, and
published in the Federal Register on
October 25, 2013, 78 FR 64018, GE
Healthcare, 3350 North Ridge Avenue,
Arlington Heights, Illinois 60004–1412,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease for distribution to
its customers.
17:33 Mar 12, 2014
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Whistleblower Protection Advisory
Committee
[FR Doc. 2014–05495 Filed 3–12–14; 8:45 am]
VerDate Mar<15>2010
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of GE
Healthcare to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. The DEA has investigated GE
Healthcare to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Jkt 232001
Nominations for WPAC must be
submitted (postmarked, sent,
transmitted, or received) by May 12,
2014.
DATES:
You may submit
nominations for WPAC, identified by
the OSHA Docket No., OSHA–2014–
0004, by any of the following methods:
Electronically: Nominations,
including attachments, may be
submitted electronically at https://
www.regulations.gov, which is the
Federal eRulemaking Portal. Follow the
instructions online for making
electronic submissions.
ADDRESSES:
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Facsimile: If your nomination and
supporting materials, including
attachments, do not exceed 10 pages,
you may fax them to the OSHA Docket
Office at (202) 693–1648.
Mail, hand delivery, express mail,
messenger or courier service: Submit
your nominations and supporting
materials to the OSHA Docket Office,
Docket No. OSHA–2014–0004, U.S.
Department of Labor, Room N–2625,
200 Constitution Avenue NW.,
Washington, DC 20210; telephone (202)
693–2350 (OSHA’s TTY number is (877)
889–5627). Deliveries (hand, express
mail, messenger and courier service) are
accepted during the Department of
Labor’s and Docket Office’s normal
business hours, 8:15 a.m.–4:45 p.m., e.t.
Instructions: All nominations and
supporting materials for WPAC must
include the Agency name and docket
number for this Federal Register notice
(Docket No. OSHA–2014–0004).
Because of security-related procedures,
submitting nominations by regular mail
may result in a significant delay in their
receipt. Please contact the OSHA Docket
Office for information about security
procedures for submitting nominations
by hand delivery, express delivery, and
messenger or courier service. For
additional information on submitting
nominations see the ‘‘Public
Participation—Submission of
Nominations and Access to Docket’’
heading in the SUPPLEMENTARY
INFORMATION section below.
Submissions in response to this
Federal Register notice, including
personal information provided, are
posted without change at https://
www.regulations.gov. Therefore, OSHA
cautions interested parties about
submitting personal information such as
social security numbers and dates of
birth.
Docket: To read or download
submissions or other material in the
docket, go to https://www.regulations.gov
or the OSHA Docket Office at the
address above. All documents in the
docket are listed in the https://
www.regulations.gov index; however,
some information (e.g., copyrighted
material) is not publicly available to
read or download through that Web site.
All submissions, including copyrighted
material, are available for inspection
and copying at the OSHA Docket Office.
FOR FURTHER INFORMATION CONTACT:
Meghan Smith, OSHA, Directorate of
Whistleblower Protection Programs,
U.S. Department of Labor, Room N–
4624, 200 Constitution Avenue NW.,
Washington, DC 20210; telephone (202)
693–2199; email address
smith.meghan.p@dol.gov.
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14299-14300]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05495]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2013, and published in the Federal
Register on October 25, 2013, 78 FR 64017, Cambrex Charles City, Inc.,
1205 11th Street, Charles City, Iowa 50616, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Opium, raw (9600).......................... II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
[[Page 14300]]
Noroxymorphone (9668)...................... II
Poppy Straw Concentrate (9670)............. II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers, for dosage form development, for
clinical trials, and for use in stability qualification studies.
No comments or objections have been received. The DEA has
considered the factors in 21 U.S.C. 823(a) and determined that the
registration of Cambrex Charles City, Inc., to manufacture the listed
basic classes of controlled substances is consistent with the public
interest at this time. The DEA has investigated Cambrex Charles City,
Inc., to ensure that the company's registration is consistent with the
public interest. The investigation has included inspection and testing
of the company's physical security systems, verification of the
company's compliance with state and local laws, and a review of the
company's background and history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-05495 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P
